Kacey Holland, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7308 Wessex Dr, Temple Hills, MD 20748 Phone: 301-343-3219 |
Kc Mac Therapeutic Services Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7103 Murphy Ct, Temple Hills, MD 20748 Phone: 240-765-9380 |
Dr. Angela C Bradford, PHD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5219 Kenstan Dr, Temple Hills, MD 20748 Phone: 301-254-6623 |
Mrs. Olisa Renee Hall, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3507 Dixon St, Temple Hills, MD 20748 Phone: 240-383-0406 |
Linda Joyce Vaughn, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4205 Lakeview Dr, Temple Hills, MD 20748 Phone: 301-848-3216 |
Communication Builders Therapeutic Services, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3507 Dixon St, Temple Hills, MD 20748 Phone: 301-485-9302 |
Penfield Play Lab, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7308 Wessex Dr, Temple Hills, MD 20748 Phone: 301-343-3219 |
Barbara Hammond Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5353 Temple Hill Rd, Temple Hills, MD 20748 Phone: 202-698-4500 |
Rachelle Nelson, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3520 Dixon St, Temple Hills, MD 20748 Phone: 240-476-8703 |
News Archive
During her medical school career, third-year student Skylar Nahi has taken advantage of the mentorship and research opportunities available to Feinberg students.
A common variation in a human gene that affects the brain's reward processing circuit increases vulnerability to the rewarding effects of the main psychoactive ingredient of cannabis in adolescent females, but not males, according to preclinical research by Weill Cornell Medicine investigators.
A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office has granted and will reissue the composition of matter patent for picoplatin as RE41209, replacing USPN 5,665,771 ('771 patent), on April 6, 2010. The reissue was applied for May 8, 2009, and, on March 17, 2010, the USPTO released the "Issue Notification" for the reissue application.
Go beyond ordinary with new arrivals from the Spring 2010 Scrubs & Beyond catalog! The latest catalog begins arriving the week of January 5th, but new spring merchandise is online now at Scrubs & Beyond.
› Verified 1 days ago